Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at ...

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving glucagon-like peptide 1 receptor agonists (GLP-1 RAs) within the context of ...

Unlock the latest advancements in obesity treatment. Expert insights reveal groundbreaking medical breakthroughs and ...

Because obesity and obesity-related conditions have been linked to several types of cancer, doctors believe that these ...

Use of GLP-1 RAs was associated with lower incidence of death-censored graft loss (adjusted subhazard ratio, 0.51) and lower mortality (adjusted hazard ratio, 0.69). GLP-1 RA use was not ...

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at the annual ...